Siegel, David

A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma

Richardson, P. G., Barlogie, B., Berenson, J., Singhal, S., Jagannath, S., Irwin, D., Rajkumar, S. V., Srkalovic, G., Alsina, M., Alexanian, R., et al. (2003) · New England Journal of Medicine

Multiple Myeloma Research and TreatmentsBone health and treatments

Cited by 2,632

Antitumor Activity of Thalidomide in Refractory Multiple Myeloma

Singhal, S., Mehta, J., Desikan, R., Ayers, D., Roberson, P., Eddlemon, P., Munshi, N., Anaissie, E., Wilson, C., Dhodapkar, M., et al. (1999) · New England Journal of Medicine

Multiple Myeloma Research and TreatmentsBone health and treatments

Cited by 2,575

Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma.

Munshi, N. C., Anderson, L. D., Shah, N., Madduri, D., Berdeja, J., Lonial, S., Raje, N., Lin, Y., Siegel, D., Oriol, A., et al. (2021) · New England Journal of Medicine

CAR-T cell therapy researchMultiple Myeloma Research and Treatments

Cited by 2,560

Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma.

Raje, N., Berdeja, J., Lin, Y., Siegel, D., Jagannath, S., Madduri, D., Liedtke, M., Rosenblatt, J., Maus, M. V., Turka, A., et al. (2019) · New England Journal of Medicine

CAR-T cell therapy researchMultiple Myeloma Research and Treatments

Cited by 1,730

Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma

Stewart, A. K., Rajkumar, S. V., Dimopoulos, M. A., Masszi, T., Špička, I., Oriol, A., Hájek, R., Rosiñol, L., Siegel, D. S., Mihaylov, G. G., et al. (2015) · New England Journal of Medicine

Multiple Myeloma Research and TreatmentsProtein Degradation and Inhibitors

Cited by 1,332

Lenalidomide plus Dexamethasone for Relapsed Multiple Myeloma in North America

Weber, D. M., Chen, C., Niesvizky, R., Wang, M., Belch, A., Stadtmauer, E. A., Siegel, D., Borrello, I., Rajkumar, S. V., Chanan-Khan, A. A., et al. (2007) · New England Journal of Medicine

Multiple Myeloma Research and TreatmentsBone health and treatments

Cited by 1,233

Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1

Rajkumar, S. V., Harousseau, J.-L., Durie, B., Anderson, K. C., Dimopoulos, M., Kyle, R., Blade, J., Richardson, P., Orlowski, R., Siegel, D., et al. (2011) · Blood

Multiple Myeloma Research and TreatmentsStatistical Methods in Clinical Trials

Cited by 1,036

Widespread Genetic Heterogeneity in Multiple Myeloma: Implications for Targeted Therapy

Lohr, J. G., Stojanov, P., Carter, S. L., Cruz-Gordillo, P., Lawrence, M. S., Auclair, D., Sougnez, C., Knoechel, B., Gould, J., Saksena, G., et al. (2014) · Cancer Cell

Multiple Myeloma Research and TreatmentsCancer Genomics and Diagnostics

Cited by 988

Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial

Rajkumar, S. V., Jacobus, S., Callander, N. S., Fonseca, R., Vesole, D. H., Williams, M. E., Abonour, R., Siegel, D. S., Katz, M., & Greipp, P. R. (2010) · The Lancet Oncology

Multiple Myeloma Research and TreatmentsBone health and treatments

Cited by 933

Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study

Dimopoulos, M., Quach, H., Mateos, M.-V., Landgren, O., Leleu, X., Siegel, D., Weisel, K., Yang, H., Klippel, Z., Zahlten-Kumeli, A., et al. (2020) · The Lancet

Multiple Myeloma Research and TreatmentsChronic Lymphocytic Leukemia Research

Cited by 430

Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study

Richardson, P. G., Siegel, D. S., Vij, R., Hofmeister, C. C., Baz, R., Jagannath, S., Chen, C., Lonial, S., Jakubowiak, A., Bahlis, N., et al. (2014) · Blood

Multiple Myeloma Research and TreatmentsProtein Degradation and Inhibitors

Cited by 381

NAD(P)H:Quinone Oxidoreductase Activity Is the Principal Determinant of β-Lapachone Cytotoxicity

Pink, J. J., Planchon, S. M., Tagliarino, C., Varnes, M. E., Siegel, D., & Boothman, D. A. (2000) · Journal of Biological Chemistry

Bioactive Compounds and Antitumor AgentsGenomics, phytochemicals, and oxidative stress

Cited by 376

Phase 1 study of the MDM2 inhibitor AMG 232 in patients with advanced P53 wild-type solid tumors or multiple myeloma

Gluck, W. L., Gounder, M. M., Frank, R., Eskens, F., Blay, J. Y., Cassier, P. A., Soria, J.-C., Chawla, S., de Weger, V., Wagner, A. J., et al. (2020) · Investigational New Drugs

Cancer-related Molecular PathwaysPI3K/AKT/mTOR signaling in cancer

Cited by 127

Orvacabtagene autoleucel (orva-cel), a B-cell maturation antigen (BCMA)-directed CAR T cell therapy for patients (pts) with relapsed/refractory multiple myeloma (RRMM): update of the phase 1/2 EVOLVE study (NCT03430011).

Mailankody, S., Jakubowiak, A. J., Htut, M., Costa, L. J., Lee, K., Ganguly, S., Kaufman, J. L., Siegel, D. S. D., Bensinger, W., Cota, M., et al. (2020) · Journal of Clinical Oncology

CAR-T cell therapy researchMultiple Myeloma Research and Treatments

Cited by 126

Comprehensive molecular profiling of multiple myeloma identifies refined copy number and expression subtypes

Skerget, S., Penaherrera, D., Chari, A., Jagannath, S., Siegel, D. S., Vij, R., Orloff, G., Jakubowiak, A., Niesvizky, R., Liles, D., et al. (2024) · Nature Genetics

Multiple Myeloma Research and TreatmentsLymphoma Diagnosis and Treatment

Cited by 95

KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma

Jagannath, S., Lin, Y., Goldschmidt, H., Reece, D., Nooka, A., Senin, A., Rodriguez-Otero, P., Powles, R., Matsue, K., Shah, N., et al. (2021) · Blood Cancer Journal

Multiple Myeloma Research and TreatmentsCAR-T cell therapy research

Cited by 90

Phase 1b trial of pembrolizumab monotherapy for relapsed/refractory multiple myeloma: KEYNOTE‐013

Ribrag, V., Avigan, D. E., Green, D. J., Wise‐Draper, T., Posada, J. G., Vij, R., Zhu, Y., Farooqui, M. Z. H., Marinello, P., & Siegel, D. S. (2019) · British Journal of Haematology

Multiple Myeloma Research and TreatmentsCancer Immunotherapy and Biomarkers

Cited by 82

Pembrolizumab combined with lenalidomide and low‐dose dexamethasone for relapsed or refractory multiple myeloma: phase I KEYNOTE‐023 study

Mateos, M., Orlowski, R. Z., Ocio, E. M., Rodríguez‐Otero, P., Reece, D., Moreau, P., Munshi, N., Avigan, D. E., Siegel, D. S., Ghori, R., et al. (2019) · British Journal of Haematology

Multiple Myeloma Research and TreatmentsMultiple Sclerosis Research Studies

Cited by 73

Indatuximab ravtansine plus dexamethasone with lenalidomide or pomalidomide in relapsed or refractory multiple myeloma: a multicentre, phase 1/2a study

Kelly, K. R., Ailawadhi, S., Siegel, D. S., Heffner, L. T., Somlo, G., Jagannath, S., Zimmerman, T. M., Munshi, N. C., Madan, S., Chanan-Khan, A., et al. (2021) · The Lancet Haematology

Multiple Myeloma Research and TreatmentsMonoclonal and Polyclonal Antibodies Research

Cited by 46

Pomalidomide plus low‐dose dexamethasone in relapsed refractory multiple myeloma after lenalidomide treatment failure

Siegel, D. S., Schiller, G. J., Song, K. W., Agajanian, R., Stockerl‐Goldstein, K., Kaya, H., Sebag, M., Samaras, C., Malek, E., Talamo, G., et al. (2020) · British Journal of Haematology

Multiple Myeloma Research and TreatmentsBone health and treatments

Cited by 46

I-OPen: inferior outcomes of penta-refractory compared to penta-exposed multiple myeloma patients

Gill, S. K., Unawane, R., Wang, S., Ahn, J., Aleman, A., Siegel, D. S., Vesole, D. H., Parmar, H., Phull, P., & Biran, N. (2022) · Blood Cancer Journal

Multiple Myeloma Research and TreatmentsChronic Lymphocytic Leukemia Research

Cited by 16